Allergan initiates new IBD clinical research programme of brazikumab. Credit: © Allergan.

Allergan has commenced two clinical research programmes, INTREPID and EXPEDITION, to assess the safety and efficacy of its investigational IL-23 inhibitor therapy called brazikumab for inflammatory bowel disease (IBD).

The multi-centre, randomised, double-blind, double-dummy, placebo-controlled and active-controlled, parallel-group Phase IIb/III INTREPID programme will evaluate brazikumab for Crohn’s disease treatment.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

During the first stage of INTREPID, brazikumab will be compared to placebo and Humira (adalimumab) in around 450 patients. In the second stage, the drug will be compared only to Humira in 690 participants.

The trial’s primary endpoints are tracking of endoscopic response and clinical remission depending on loose stool frequency and abdominal pain scores.

EXPEDITION is an ulcerative colitis programme designed to begin with a multi-centre, randomised, double-blind, double-dummy, placebo-controlled and active-controlled, parallel-group Phase II trial.

“These programmes are part of our growing focus in gastroenterology, which will become even more significant for Allergan in the coming years.”

In this programme, brazikumab will be compared to placebo or Entyvio (vedolizumab) in about 375 subjects. The primary endpoints of EXPEDITION are same as INTREPID, however, the evaluations will be based on loose stool frequency and rectal bleeding.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

EXPEDITION is currently enrolling patients, while INTREPID is expected to begin the recruitment in December this year.

Both programmes have a personalised approach and will evaluate the role of biomarkers in predicting treatment response to brazikumab. Observations from the Phase II EXPEDITION trial will be applied to its planned Phase III part.

Allergan chief R&D officer David Nicholson said: “The personalised study design of the INTREPID and EXPEDITION research programmes reflect Allergan’s commitment to finding new approaches in how we address the needs of patients with our medicines.

“These programmes are part of our growing focus in gastroenterology, which will become even more significant for Allergan in the coming years.”

Allergan’s prior Phase II clinical trial of brazikumab demonstrated higher anti-inflammatory response and remission rates in Crohn’s disease patients who had higher levels of a key IBD biomarker compared to those with lower levels.